Nelly ZIADE 🍀 Nellziade
1 month 3 weeks ago
💉 Risankizumab durable in #PsA?
#POS0047 3 RCT n=964 KEEPsAKE
Yes! ACR50 ~37% & MDA ~34% @w244
no new safety signals 💪
#EULAR2026 @RheumNow https://t.co/911Fi9vxfP
Nelly ZIADE 🍀 Nellziade
1 month 3 weeks ago
🤔 Best endpoint for #PsA trials?
#POS0046: GRAPPA-OMERACT NMA (24 trials, n=12,000):
MDA wins! (OR 5.06) 📊
#EULAR2026 @RheumNow https://t.co/3KWaKcvF0a
Nelly ZIADE 🍀 Nellziade
1 month 3 weeks ago
🤔 GUS or IL-17i for #PsA?
#POS0045: RW study:
Both! ~76% persistence & similar effectiveness
1141 pts @12mo #PsABIOnd 🌍
#EULAR2026 @RheumNow https://t.co/PyuaH5B5V1
Jiha Lee JihaRheum
1 month 3 weeks ago
In #PsA, obesity isn't just a comorbidity, it's a disease modifier. Pooled SPIRIT trials (n=1284): 43% had obesity. BMI≥30 vs normal: joint counts ↑, function ↓, fatigue ↑, CVD 55% vs 18%, HTN 52% vs 11%, DM 19% vs 3%. @RheumNow #EULAR2026 POS0460
Janet Pope Janetbirdope
1 month 3 weeks ago
Does #Rx w #immunesuppression w
#antifibrotic
Help #SARD-ILD?
YES.
N=40 SARD-ILD, 1/2 w UIP pattern
Use of #IS w #antifibrotic pt group had better survival
Small N and ?channeling bias
But interesting results
TAke home : Use IS + antifibrotic
#EULAR2026 #POS0530
@RheumNow https://t.co/tfxVVw27jJ
Jiha Lee JihaRheum
1 month 3 weeks ago
Guselkumab in erosive #PsA: ACR20 68% vs 47% placebo, structural damage progression ↓ across subgroups regardless of sex, BMI, MTX use, or joint counts. Highest inflammation and erosion burden? Biggest benefit. IL-23i holds up where it matters most. @RheumNow #EULAR2026 POS0480
Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare. Recent anecdotal reports suggest that CD19-directed chimeric antigen receptor T (CAR-T) cell therapy may be an effective approach.
Jiha Lee JihaRheum
1 month 3 weeks ago
Not all "difficult-to-treat" #PsA definitions are equal. Real-world DEPAR cohort (n=885): 20% met GRAPPA complex-to-manage vs only 4% EULAR difficult-to-manage criteria. Definition choice determines who gets identified, and who gets left behind. @RheumNow #EULAR2026 POS0446
Md Yuzaiful Md Yusof Yuz6Yusof
1 month 3 weeks ago
#EULAR2026 POS0044 TO ASPIRIN OR NOT in asymptomatic antiphospholipid antibodies (aPL) carriers? A study in Spain reported 4.6% VTE & 4.1% ATE.
-Aspirin reduced thrombosis without increasing bleeding risk in asymptomatic aPL inc. those <3 lab points (isolated LA) @RheumNow https://t.co/NyVjAfjAKd
sheila RHEUMarampa
1 month 3 weeks ago
SLE & Dengue infxn?
This pop’n study from Brazil showed that #SLE pts who developed #dengue had sig. higher rates of mortality, DHF & hospital stay length vs. gen popn
These factors were found to have strong independent assoc w/SLE.
Abs010 @rheumnow #EULAR2026 https://t.co/DTDPiQRlAf
Jiha Lee JihaRheum
1 month 3 weeks ago
IL-23i vs IL-17i in PsABIOnd (n=1,141): 12mo persistence (~77%), joint/skin response, MDA, and PROs similar across both. GUS matched IL-17i despite treating more biologic-experienced pts (15% vs 8% on 4th-line). GI AEs higher with IL-17i (11% vs 7%). @RheumNow #EULAR2026 POS0045
Antoni Chan MD (Prof) synovialjoints
1 month 3 weeks ago
What’s new in (WIN) PsA session. A preview of the BE BOLD study: Bimekizumab vs risankizumab on ACR50 in active #PsA 49.1% vs 38.4% (p=0.008). The first head-to-head biologic trial to show joint superiority in PsA. Dual IL-17A/F blockade important. Abstr #LB0001 @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof
1 month 3 weeks ago
#EULAR2026 POS0440 1-Year Open Label Extension Study of 6-monthly Inebilizumab, a CD19 depleter in #IgG4 disease:
-No flare in INEB group; 6% flare in PBO-INEB
-10.9% serious infections
-1 pt discontinued due to low IgG
Interested to see longer-term safety data @RheumNow https://t.co/PPUw81T8DZ
Nelly ZIADE 🍀 Nellziade
1 month 3 weeks ago
What’s in the pipeline for #psoriatic_arthritis treatment?
A special focus on Tyk2 inhibitors
WIN session at #EULAR2026
@RheumNow https://t.co/dDJtmdx9xU
Aurelie Najm AurelieRheumo
1 month 3 weeks ago
What is new in PsA?
Dennis McGonagle's take at #EULAR2026
-a strong year for discovery in mechanisms of transition from PSO to PsA
-publication of the first single cell atlas Enthesis
-Better understanding of VTE mechanisms in JAKi in PsA
-clinical aspects of Axial involvement https://t.co/v9cfn1y4fH
